At week 52 , further reductions with insulin titration resulted in changes from baseline in HbA1c of -0.81 0.08 % ( -8.9 0.9 mmol/mol ) , -1.18 0.08 % ( -12.9 0.9 mmol/mol ) , and -1.27 0.08 % ( -13.9 0.9 mmol/mol ) with placebo , empagliflozin 10 mg , and empagliflozin 25 mg , respectively , and final HbA1c of 7.5 % ( 58 mmol/mol ) , 7.2 % ( 55 mmol/mol ) , and 7.1 % ( 54 mmol/mol ) , respectively .